First Time Loading...

Harpoon Therapeutics Inc
NASDAQ:HARP

Watchlist Manager
Harpoon Therapeutics Inc Logo
Harpoon Therapeutics Inc
NASDAQ:HARP
Watchlist
Price: 23.01 USD
Updated: Apr 19, 2024

Intrinsic Value

HARP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. [ Read More ]

The intrinsic value of one HARP stock under the Base Case scenario is 11.25 USD. Compared to the current market price of 23.01 USD, Harpoon Therapeutics Inc is Overvalued by 51%.

Key Points:
HARP Intrinsic Value
Base Case
11.25 USD
Overvaluation 51%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Harpoon Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HARP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Harpoon Therapeutics Inc

Provide an overview of the primary business activities
of Harpoon Therapeutics Inc.

What unique competitive advantages
does Harpoon Therapeutics Inc hold over its rivals?

What risks and challenges
does Harpoon Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Harpoon Therapeutics Inc recently?

Summarize the latest earnings call
of Harpoon Therapeutics Inc.

What significant events have occurred
in Harpoon Therapeutics Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Harpoon Therapeutics Inc.

Provide P/S
for Harpoon Therapeutics Inc.

Provide P/E
for Harpoon Therapeutics Inc.

Provide P/OCF
for Harpoon Therapeutics Inc.

Provide P/FCFE
for Harpoon Therapeutics Inc.

Provide P/B
for Harpoon Therapeutics Inc.

Provide EV/S
for Harpoon Therapeutics Inc.

Provide EV/GP
for Harpoon Therapeutics Inc.

Provide EV/EBITDA
for Harpoon Therapeutics Inc.

Provide EV/EBIT
for Harpoon Therapeutics Inc.

Provide EV/OCF
for Harpoon Therapeutics Inc.

Provide EV/FCFF
for Harpoon Therapeutics Inc.

Provide EV/IC
for Harpoon Therapeutics Inc.

Show me price targets
for Harpoon Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Harpoon Therapeutics Inc?

How accurate were the past Revenue estimates
for Harpoon Therapeutics Inc?

What are the Net Income projections
for Harpoon Therapeutics Inc?

How accurate were the past Net Income estimates
for Harpoon Therapeutics Inc?

What are the EPS projections
for Harpoon Therapeutics Inc?

How accurate were the past EPS estimates
for Harpoon Therapeutics Inc?

What are the EBIT projections
for Harpoon Therapeutics Inc?

How accurate were the past EBIT estimates
for Harpoon Therapeutics Inc?

Compare the revenue forecasts
for Harpoon Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Harpoon Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Harpoon Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Harpoon Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Harpoon Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Harpoon Therapeutics Inc with its peers.

Analyze the financial leverage
of Harpoon Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Harpoon Therapeutics Inc.

Provide ROE
for Harpoon Therapeutics Inc.

Provide ROA
for Harpoon Therapeutics Inc.

Provide ROIC
for Harpoon Therapeutics Inc.

Provide ROCE
for Harpoon Therapeutics Inc.

Provide Gross Margin
for Harpoon Therapeutics Inc.

Provide Operating Margin
for Harpoon Therapeutics Inc.

Provide Net Margin
for Harpoon Therapeutics Inc.

Provide FCF Margin
for Harpoon Therapeutics Inc.

Show all solvency ratios
for Harpoon Therapeutics Inc.

Provide D/E Ratio
for Harpoon Therapeutics Inc.

Provide D/A Ratio
for Harpoon Therapeutics Inc.

Provide Interest Coverage Ratio
for Harpoon Therapeutics Inc.

Provide Altman Z-Score Ratio
for Harpoon Therapeutics Inc.

Provide Quick Ratio
for Harpoon Therapeutics Inc.

Provide Current Ratio
for Harpoon Therapeutics Inc.

Provide Cash Ratio
for Harpoon Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Harpoon Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Harpoon Therapeutics Inc?

What is the current Free Cash Flow
of Harpoon Therapeutics Inc?

Financials

Balance Sheet Decomposition
Harpoon Therapeutics Inc

Current Assets 34.3m
Cash & Short-Term Investments 31.6m
Other Current Assets 2.7m
Non-Current Assets 13.3m
PP&E 12.4m
Other Non-Current Assets 900k
Current Liabilities 18.1m
Accounts Payable 3.4m
Accrued Liabilities 14.7m
Non-Current Liabilities 24.9m
Long-Term Debt 8.8m
Other Non-Current Liabilities 16.1m
Efficiency

Earnings Waterfall
Harpoon Therapeutics Inc

Revenue
37.3m USD
Operating Expenses
-74.7m USD
Operating Income
-37.4m USD
Other Expenses
6.9m USD
Net Income
-30.5m USD

Free Cash Flow Analysis
Harpoon Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

HARP Profitability Score
Profitability Due Diligence

Harpoon Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive 1-Year Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
18/100
Profitability
Score

Harpoon Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

HARP Solvency Score
Solvency Due Diligence

Harpoon Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
Average D/E
47/100
Solvency
Score

Harpoon Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HARP Price Targets Summary
Harpoon Therapeutics Inc

Wall Street analysts forecast HARP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HARP is 24.14 USD with a low forecast of 23.23 USD and a high forecast of 28.35 USD.

Lowest
Price Target
23.23 USD
1% Upside
Average
Price Target
24.14 USD
5% Upside
Highest
Price Target
28.35 USD
23% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

HARP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HARP Price
Harpoon Therapeutics Inc

1M 1M
-
6M 6M
+296%
1Y 1Y
+265%
3Y 3Y
-88%
5Y 5Y
-80%
10Y 10Y
-83%
Annual Price Range
23.01
52w Low
3.29
52w High
23.01
Price Metrics
Average Annual Return -21.96%
Standard Deviation of Annual Returns 62.51%
Max Drawdown -99%
Shares Statistics
Market Capitalization 492.3m USD
Shares Outstanding 21 397 200
Percentage of Shares Shorted 3.24%

HARP Return Decomposition
Main factors of price return

What is price return decomposition?

HARP News

Other Videos

Last Important Events
Harpoon Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Harpoon Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Harpoon Therapeutics Inc Logo
Harpoon Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

492.3m USD

Dividend Yield

0%

Description

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.

Contact

CALIFORNIA
South San Francisco
131 Oyster Point Blvd Ste 300
+16504437400.0
https://www.harpoontx.com/

IPO

2019-02-08

Employees

99

Officers

President, CEO, Secretary & Director
Ms. Julie M. Eastland M.B.A.
Chief Medical Officer
Dr. Luke N. Walker M.D.
Interim Chief Financial Officer
Mr. Michael Eric Faerm
Senior Vice President of Product Development, Technical & Manufacturing Operations
Dr. Chatan Charan Ph.D.
Chief Legal Officer
Mr. James B. Bucher J.D.
Chief People Officer
Ms. Wendy Chang
Show More
Senior Vice President of Translational Medicine
Dr. Banmeet Anand Ph.D.
Senior Vice President of Business Development
Mr. Haibo Wang
Show Less

See Also

Discover More
What is the Intrinsic Value of one HARP stock?

The intrinsic value of one HARP stock under the Base Case scenario is 11.25 USD.

Is HARP stock undervalued or overvalued?

Compared to the current market price of 23.01 USD, Harpoon Therapeutics Inc is Overvalued by 51%.